Want to see UTMD full AI Analyst Report?
Utah Medical Products (UTMD) AI Stock Analysis
Utah Medical Products
(NASDAQ:UTMD)
UTMD scores well primarily due to strong financial quality—high margins, strong cash conversion, and a near-debt-free balance sheet—partly offset by ongoing revenue and free-cash-flow contraction. Technicals are largely neutral, valuation is reasonable but not discounted, and the Orion acquisition provides a constructive (but execution-dependent) growth catalyst.
Utah Medical Products Key Performance Indicators (KPIs)
Utah Medical Products (UTMD) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $225.47M
- Dividend Yield
- 1.72%
- Average Volume (3M)
- 36.73K
- Price to Earnings (P/E)
- 21.3
- Beta (1Y)
- 0.46
- Revenue Growth
- -9.62%
- EPS Growth
- ―
- Country
- US
- Employees
- 146
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Instruments & Supplies
Utah Medical Products Business Overview & Revenue Model
Company Description
Utah Medical Products, Inc. (UTMD) is a healthcare technology company focused on the creation, production, and supply of medical devices for the healthcare sector. UTMD offers a comprehensive portfolio of medical devices primarily serving labor and d...
How the Company Makes Money
UTMD makes money by selling medical devices and related components to healthcare customers, generating revenue largely from product sales rather than services. A core driver is recurring demand for single-use/disposable products used in routine hospi...
Utah Medical Products Financial Statement Overview
Summary
Financial health is strong: high profitability (TTM gross margin ~55%, net margin ~29%), strong cash conversion (FCF ~97% of net income), and an exceptionally conservative balance sheet (near-zero leverage with debt-to-equity ~0.002). The primary drag is weakening business momentum, with multi-period revenue contraction and shrinking free cash flow (TTM FCF down ~12%), alongside some margin softening versus prior highs.
Income Statement
74PositiveBalance Sheet
93Very PositiveCash Flow
79Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 34.92M | 38.52M | 40.90M | 50.22M | 52.28M | 49.05M |
| Gross Profit | 20.14M | 22.00M | 24.14M | 30.04M | 32.20M | 30.92M |
| EBITDA | 14.87M | 17.06M | 19.65M | 24.75M | 27.74M | 26.34M |
| Net Income | 10.64M | 11.29M | 13.87M | 16.64M | 16.47M | 14.79M |
Balance Sheet | ||||||
| Total Assets | 128.50M | 122.54M | 122.54M | 135.46M | 123.87M | 115.64M |
| Cash, Cash Equivalents and Short-Term Investments | 85.20M | 85.76M | 82.98M | 92.87M | 75.05M | 60.97M |
| Total Debt | 180.00K | 225.00K | 338.00K | 295.00K | 341.00K | 396.00K |
| Total Liabilities | 5.22M | 3.27M | 5.11M | 7.14M | 9.62M | 8.50M |
| Stockholders Equity | 123.28M | 119.27M | 117.43M | 128.31M | 114.25M | 107.14M |
Cash Flow | ||||||
| Free Cash Flow | 7.60M | 14.32M | 14.60M | 21.64M | 20.33M | 20.65M |
| Operating Cash Flow | 7.97M | 14.69M | 14.83M | 22.28M | 21.15M | 21.20M |
| Investing Cash Flow | -373.00K | -371.00K | -208.00K | -639.00K | -818.00K | -552.00K |
| Financing Cash Flow | -4.15M | -12.34M | -23.84M | -4.17M | -5.48M | -10.90M |
Utah Medical Products Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For UTMD, the sentiment is Neutral. The current price of 72.23 is below the 20-day moving average (MA) of 72.79, below the 50-day MA of 72.80, and above the 200-day MA of 67.82, indicating a neutral trend. The MACD of -0.87 indicates Positive momentum. The RSI at 45.65 is Neutral, neither overbought nor oversold. The STOCH value of 52.26 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for UTMD.
Utah Medical Products Risk Analysis
Utah Medical Products disclosed 10 risk factors in its most recent earnings report. Utah Medical Products reported the most risks in the "Legal & Regulatory" category.
Latest Risks Added
0 New RisksUtah Medical Products Peers Comparison
Overall Rating
INFU75Outperform- UTMD75Outperform
KRMD51Neutral
SMTI46Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| INFU | 75Outperform | $270.08M | 29.11 | 15.77% | ― | 2.40% | 76.01% |
| UTMD | 75Outperform | $202.40M | 21.27 | 8.78% | 1.72% | -9.62% | ― |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| KRMD | 51Neutral | $139.90M | -78.83 | -10.63% | ― | 22.41% | 60.02% |
| SMTI | 46Neutral | $290.43M | -8.49 | -473.55% | ― | 12.93% | -219.19% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| UTMD | Utah Medical Products | 72.23 | 16.03 | 28.53% | |
| INFU | InfuSystem Holdings, Inc. | 13.69 | 3.60 | 35.68% | |
| KRMD | Repro-Med Systems, Inc. | 3.09 | -0.83 | -21.17% | |
| SMTI | Sanara MedTech | 31.55 | 3.39 | 12.04% |
Utah Medical Products Corporate Events
Utah Medical Products Expands Via Orion Medical Acquisition
PositiveOn August 31, 2026, Femcare Ltd., a wholly owned subsidiary of Utah Medical Products, Inc., completed the acquisition of all common shares of UK-based Orion Medical Supplies Ltd, a niche assembler and distributor of harm reduction medical device kits...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Sep 06, 2026